Pipeline Overview

The TRACON clinical pipeline includes a monoclonal antibody (TRC105) and one small molecule (TRC102).

TRC105                           
TRC105 is a human chimeric monoclonal antibody to CD105 (also known as endoglin), a target that is essential for angiogenesis. TRC105 is expected to address multiple solid tumor types including breast, kidney, prostate, ovarian, lung, liver, and bladder cancer. A Phase 1 trial of TRC105 monotherapy in patients with advanced cancer is complete, and Phase 1b and Phase 2 trials are ongoing in multiple cancer indications.  TRC105 will also be developed as a treatment for age-related macular degeneration ("AMD"), the most common cause of blindness in the western world.

TRC105 Scientific Presentations:
2010 SUO Meeting - Phase 1 poster, prostate cancer
2010 AACR Meeting – preclinical poster
2009 AACR Meeting – preclinical poster
2011 ASCO Meeting Duke biomarker poster
2011 ASCO Meeting Phase 1 slide show
2011 ASCO Meeting Phase 1 poster

TRC102
TRC102 is a small molecule inhibitor of base-excision repair intended to reverse resistance to alkylator and antimetabolite chemotherapy, including agents used in the treatment of malignant melanoma, malignant glioma, and lung cancer. A Phase 1 study of TRC102 in combination with Alimta® chemotherapy was successfully completed, and two ongoing Phase 1 studies are evaluating TRC102 in combination with Temodar® chemotherapy and Fludara® chemotherapy. Phase 2 studies will evaluate the combination of TRC102 and Alimta® in lung cancer, and additional Phase 2 studies are planned in multiple solid tumor indications.

TRC102 Scientific Presentations:
2010 ASCO - Phase 1 slideshow
2010 ASCO - Phase 1 poster
2010 AACR– preclinical poster
2009 AACR– 3 preclinical posters
2007 EORTC-NCI-AACR